U.N. agencies are warning that “a new” drug that was previously found in India to treat meningitis could soon become available in the United States.
The drug, known as fluoroquinolones, or fenofibrates, was made by Pfizer, the world’s largest pharmaceutical company.
In February, the FDA approved the drug for use in patients with meningococcal disease and pneumonia, two of the most common infections.
But that approval is still pending, which means that the drug is not yet available to the general public.
The FDA also issued a public comment asking for more information on the drug’s safety.
FDA officials said that “in light of the new information, the agency cannot comment further.”
It’s unclear how much the drug will cost, but according to the New York Times, Pfizer will be paying about $8,000 for a month’s supply.
Pfizer has said that it has no plans to manufacture the drug in the U..
S., but that could change.
“We are exploring the possibility of working with Pfizer to develop a new product that would meet FDA’s safety and efficacy standards,” Pfizer said in a statement.
The company said it’s “investigating” how it might move forward with its research.
The FDA has also been cracking down on drugs made by companies that manufacture the generic versions of the medicines.
It is investigating how it will respond to the new drug.
Last year, the Obama administration suspended imports of more than 5,000 fluoroquine-brand drugs, including fluoroq, and shut down about half of the factories that produce them.
The suspension came as the number of cases of fluoroqualine-resistant strains of the bacteria that cause meningial pneumonia and pneumonia in adults shot up from 5,988 in 2011 to 21,977 last year.
Last year, about 1,500 people in the country died from the bacteria.
Pfizer said the FDA suspension was “based on a number of factors including the safety of the drug and its production process, and we are committed to fully comply with all applicable laws, rules and regulations.”
It added that the company is working with FDA and the Centers for Disease Control and Prevention to develop an alternative for its fenotroquine.
FDA said it will continue to closely monitor the situation and will take appropriate action if necessary.